Gracias Pharmaceuticals (Opc) Profile
Key Indicators
- Authorised Capital ₹ 10.00 K
- Paid Up Capital ₹ 10.00 K
- Company Age 6 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 131.12%
- Profit Growth -115.45%
- Ebitda -215.40%
- Net Worth -155.95%
- Total Assets 154.80%
About Gracias Pharmaceuticals (Opc)
Gracias Pharmaceuticals (Opc) Private Limited (GPOPL) is a Company incorporated in India on 25 October 2018 (Six years and three months 24 days old ). Its registered office is in East Delhi, Delhi, India.
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 10.00 K and a paid-up capital of Rs 10.00 K , as per Ministry of Corporate Affairs (MCA) records.
Vishnu Dutt serves as a director at the Company.
Company Details
-
Location
East Delhi, Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999DL2018OPC341141
-
Company No.
341141
-
Incorporation Date
25 Oct 2018
-
Date of AGM
-
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Gracias Pharmaceuticals (Opc)?
Board Members (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vishnu Dutt
|
Director | 25-Oct-2018 | Current |
Financial Performance of Gracias Pharmaceuticals (Opc).
Gracias Pharmaceuticals (Opc) Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 131.12% increase. The company also saw a substantial fall in profitability, with a 115.45% decrease in profit. The company's net worth observed a substantial decline by a decrease of 155.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Gracias Pharmaceuticals (Opc)?
Unlock access to Gracias Pharmaceuticals (Opc)'s control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
-
Llamativo Consulting Private LimitedVishnu Dutt is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Gracias Pharmaceuticals (Opc)?
Unlock and access historical data on people associated with Gracias Pharmaceuticals (Opc), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Gracias Pharmaceuticals (Opc), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Gracias Pharmaceuticals (Opc)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.